The Profusa, Inc. (Nasdaq: PFSA) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. Profusa is a commercial stage digital health and medical technology company focused on tissue-integrated biosensors and its Lumee Oxygen tissue monitoring platform, and its filings offer detailed insight into its capital structure, governance, financing arrangements and listing status.
Through this page, users can review current reports on Form 8-K where Profusa discloses material events such as securities purchase agreement amendments, senior secured convertible promissory note modifications, equity line of credit approvals, Nasdaq listing notifications, and manufacturing or commercial milestones referenced in Regulation FD disclosures. These 8-K filings explain key terms of convertible notes, floor price adjustments, tranche structures and mandatory prepayment provisions tied to equity line proceeds.
Investors can also access proxy statements on Schedule 14A, which describe special meetings of stockholders convened to approve items such as potential issuance of more than 19.99% of outstanding shares upon conversion of senior secured convertible notes, increases in authorized common shares, and proposals authorizing the board to implement one or more reverse stock splits within a specified ratio range. These documents outline the board’s recommendations, voting requirements and the rationale behind each corporate action.
Additional filings include registration statements on Form S-1 and related amendments, which detail resale registrations for shares issuable upon conversion of Profusa’s notes, as well as the company’s status as an emerging growth company and smaller reporting company. Notifications of late filing on Form 12b-25 explain timing for quarterly reports when additional time is needed to finalize disclosures.
On Stock Titan, each Profusa filing is accompanied by AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand complex financing terms, proposed charter amendments, or Nasdaq compliance updates. Real-time integration with EDGAR ensures that new 8-Ks, S-1 amendments, proxy statements and other PFSA filings appear promptly, while insider transaction reports on Form 4 and periodic reports such as 10-K and 10-Q (when filed) can be browsed and compared over time.
This page is designed to help investors, analysts and other interested readers interpret Profusa’s regulatory disclosures around its Lumee biosensor platform, capital-raising activities, authorized share changes and potential reverse stock splits using concise AI explanations alongside the full official documents.
Schedule 13G filed 24-Jul-2025 shows a group comprised of Ascent Partners Fund LLC, Dominion Capital and related entities plus individuals Mikhail Gurevich, Gennadiy Gurevich and Alon Brenner collectively own 3,359,068 Profusa (PFSA) common shares, equal to 9.99 % of shares outstanding as of 11-Jul-2025. The stake includes up to 820,475 shares issuable on conversion of a convertible promissory note; the note carries a 9.99 % ownership “blocker,” limiting additional conversions. All voting and dispositive power is reported as shared; no party claims sole control.
The percentage is calculated against the company’s 32,788,877 shares outstanding disclosed in a 18-Jul-2025 8-K. Because the filing is on Form 13G rather than 13D, the group certifies the position is passive and not intended to influence control. Exhibit 1 contains a joint filing agreement. The presence of an institutional investor group near the 10 % threshold signals outside confidence but also points to potential future dilution should the remaining note principal be converted once the blocker is lifted or expires.